Related references
Note: Only part of the references are listed.IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
Hong Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Irene Caruso et al.
METABOLITES (2022)
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
Giulia Ferrannini et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Standards of Care in Diabetes—2023 Abridged for Primary Care Providers
Clinical Diabetes (2022)
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Saverio Muscoli et al.
PHARMACEUTICS (2022)
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication With Adverse Outcomes in Older Cancer Patients
Li-Ju Chen et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2021)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Juan P. Frias et al.
DIABETES CARE (2021)
Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist
Filippo Mariano et al.
JOURNAL OF NEPHROLOGY (2021)
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
Samit Ghosal et al.
SCIENTIFIC REPORTS (2021)
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
Panagiotis-Nikolaos Lalagkas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Djordje S. Popovic et al.
DIABETES THERAPY (2021)
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2021)
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints
Josip A. Borovac et al.
KARDIOLOGIA POLSKA (2021)
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
Miguel Melo et al.
DIABETOLOGY & METABOLIC SYNDROME (2021)
Factors Associated with Medication Non-Adherence among Patients with Multimorbidity and Polypharmacy Admitted to an Intermediate Care Center
Javier Gonzalez-Bueno et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Won Euh et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Polypharmacy in the Management of Arterial Hypertension-Friend or Foe?
Camelia Cristina Diaconu et al.
MEDICINA-LITHUANIA (2021)
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Emily Brown et al.
ANNALS OF MEDICINE (2021)
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist
John D. Bucheit et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Relationship between hypoglycaemia, cardiovascular outcomes, and empagilflozin treatment in the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2020)
Polypharmacy: A general review of definitions, descriptions and determinants
Jordan Guillot et al.
THERAPIE (2020)
Oral semaglutide in type 2 diabetes
Sarah L. Anderson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Kelsey H. Sheahan et al.
POSTGRADUATE MEDICAL JOURNAL (2020)
The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
Pantelis A. Sarafidis et al.
CLINICAL KIDNEY JOURNAL (2020)
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints
D. Patoulias et al.
DIABETES & METABOLISM (2020)
Insulin and Exendin-4 Reduced Mutated Huntingtin Accumulation in Neuronal Cells
Silvia Rea et al.
FRONTIERS IN PHARMACOLOGY (2020)
SGLT2i: beyond the glucose-lowering effect
Lihua Ni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
Hung-Yi Chen et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Chronic kidney disease as a cardiovascular risk factor
Rafael Carmena et al.
JOURNAL OF HYPERTENSION (2020)
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
Jessica A. Huthmacher et al.
DIABETES CARE (2020)
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Mohammad S. Kuchay et al.
DIABETOLOGIA (2020)
Twin epidemics of covid-19 and non-communicable disease
Trevor A. Sheldon et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Alexandros Sachinidis et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Andre J. Scheen
NATURE REVIEWS ENDOCRINOLOGY (2020)
Wholegrain Consumption and Risk Factors for Cardiorenal Metabolic Diseases in Chile: A Cross-Sectional Analysis of 2016-2017 Health National Survey
Fabian Lanuza et al.
NUTRIENTS (2020)
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial
Wen-Huan Feng et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study
Yunwen Xu et al.
PLOS ONE (2019)
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
Salvatore Carbone et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Metformin in 2019
James Flory et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department
Elena-Codruta Dobrica et al.
MEDICINA-LITHUANIA (2019)
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA- REG OUTCOME Trial
David Fitchett et al.
CIRCULATION (2019)
Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review
Joanna Ulley et al.
BMC GERIATRICS (2019)
Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
Tamara Y. Milder et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease
Wei-Hao Hsu et al.
ONCOTARGET (2018)
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist
Sylvie Hall et al.
CLINICAL PHARMACOKINETICS (2018)
SGLT2 inhibition and kidney protection
Josselin Nespoux et al.
CLINICAL SCIENCE (2018)
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Bernard Zinman et al.
DIABETES CARE (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEA (R) trial
Naveed Sattar et al.
DIABETOLOGIA (2018)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke Post Hoc Analysis From the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Predictors of polypharmacy among elderly Thais with depressive and anxiety disorders: findings from the DAS study
Nahathai Wongpakaran et al.
BMC GERIATRICS (2018)
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
The Need for Actions Against Polypharmacy in Older People With Frailty
Taro Kojima
ANNALS OF GERIATRIC MEDICINE AND RESEARCH (2018)
Dulaglutide for the treatment of type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
William M. Steinberg et al.
DIABETES CARE (2017)
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
A. Dutour et al.
DIABETES OBESITY & METABOLISM (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Lack of Clinically Relevant Drug-Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
Sreeraj Macha et al.
CLINICAL THERAPEUTICS (2013)
Share Paper
